Soluble and matrix-associated heparan sulfate proteoglycans increase expression of erb-B2 and erb-B3 in colon cancer cell lines

被引:3
|
作者
Zvibel, I
Brill, S
Halpern, Z
Moskovitz, S
Yayon, A
Papa, M
机构
[1] Tel Aviv Med Ctr & Sch Med, Gastroenterol Inst, Liver Metastasis Res Grp, Tel Aviv, Israel
[2] Shiba Med Ctr, Dept Surg Oncol, Tel Hashomer, Israel
[3] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel
关键词
extracellular matrix; colon cancer; heparan sulfate;
D O I
10.1002/1097-0215(200002)9999:9999<::AID-IJC1045>3.0.CO;2-O
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the effect of hepatocyte-derived extracellular matrix (ECM) on the expression of erb-B2 and erb-B3 in colon cancer cell lines, as well as the role of erb-B2 and erb-B3 in colon cancer cell proliferation, Colon cancer cell lines plated on hepatocyte-derived ECM had increased protein levels of both erb-B2 and erb-B3, The addition of soluble recombinant proteoglycan syndecan-4 also resulted in higher expression of erb-B2 and erb-B3. We prepared hepatocyte-derived ECM from 1 to 7 days' cultures of hepatocytes, which contained different amounts of sulfated glycosaminoglycans. There was a direct correlation between the amounts of sulfated glycosaminoglycans in the ECM and the levels of erb-B2 and erb-B3 in the colon cell line KM12. The stimulatory effect of hepatocyte-derived ECM was abolished when the colon cancer cells were cultured in the presence of antibodies to erb-B2 These studies show that hepatocyte-derived ECM and the heparan sulfate proteoglycans present in it are responsible for inducing erb-B2 and erb-B3 in colon cancer cells. The growth stimulatory effect of extracellular matrix is mediated, at least in part, by increased expression of erb-B2. and erb-B3. (C) 2001 Wiley-Liss. Inc.
引用
收藏
页码:316 / 321
页数:6
相关论文
共 37 条
  • [1] Silibinin's effect on total EGFR, Erb-b2, and Erb-b3 expression in human colon cancer
    Hogan, F.
    Krishnegowda, N. K.
    Kahlenberg, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] DISTRIBUTION OF ERB-B2, ERB-B3, AND ERB-B4 IN THE DEVELOPING AVIAN NERVOUS-SYSTEM
    FRANCOEUR, JR
    RICHARDSON, PM
    DUNN, RJ
    CARBONETTO, S
    JOURNAL OF NEUROSCIENCE RESEARCH, 1995, 41 (06) : 836 - 845
  • [3] Expression of growth factor receptor family members EGFR, erb-B2, erb-B3 and erb-B4 in oral squamous cell carcinomas.
    Dissanayake, U
    Gullick, WJ
    Johnson, NW
    Warnakulasuriya, S
    JOURNAL OF PATHOLOGY, 2000, 190 : 56A - 56A
  • [4] Effects of X-ray irradiation on the overexpression of HER2/Erb-B2 on breast cancer cell lines
    Juranic, ZD
    Borojevic, N
    Jovanovic, D
    Stanojevic-Bakic, N
    Zizak, Z
    Neskovic-Konstantinovic, Z
    Saric, N
    Stanojkovic, T
    Raonic, T
    Milosevic, D
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2004, 23 (04) : 675 - 680
  • [5] Expression of epidermal growth factor receptor, Erb-B2 and matrix metalloproteinase-9 in hepatolithiasis and cholangiocarcinoma
    Kim, HJ
    Kim, KO
    Yim, HJ
    Yeon, JE
    Park, JJ
    Shim, JJ
    Kim, JS
    Byun, KS
    Bak, YT
    Lee, CH
    GASTROENTEROLOGY, 2003, 124 (04) : A220 - A220
  • [6] Investigation of triple helix-forming oligonucleotides as modulators of gene expression in erb-B2 positive breast cancer.
    Dolan, C
    Wogan, A
    Lawler, M
    McCann, SR
    Hollywood, D
    BRITISH JOURNAL OF CANCER, 1999, 80 : 22 - 22
  • [7] CHEMOTHERAPEUTIC INHIBITION OF ERB-B2 ONCOGENE EXPRESSION ON A NON-SMALL-CELL CANCER LINE (NSCLC-N6) BY MARINE SUBSTANCES
    ROUSSAKIS, C
    CHARRIER, J
    RIOU, D
    BIARD, JF
    MALOCHET, C
    MEFLAH, K
    VERBIST, JF
    ANTI-CANCER DRUG DESIGN, 1994, 9 (02): : 119 - 128
  • [8] Heparin-derived disaccharides modulate proliferation and erb-B2-mediated signal transduction in colon cancer cell lines
    Fishman, S
    Brill, S
    Papa, M
    Halpern, Z
    Zvibel, I
    INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (02) : 179 - 184
  • [9] Immunohistochemical expression of signaling molecules Erb-B3, MKP-3, and Stat1 in non-small cell lung carcinoma
    Kulich, S. M.
    Cagle, P. T.
    Cozza, E. M.
    Land, S. R.
    Lenzner, D.
    Brcic, L.
    Dacic, S.
    MODERN PATHOLOGY, 2008, 21 : 345A - 345A
  • [10] Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2 -: 39810:: A Phase II trial of cancer and leukemia group B
    Clamon, G
    Herndon, J
    Kern, J
    Govindan, R
    Garst, J
    Watson, D
    Green, M
    CANCER, 2005, 103 (08) : 1670 - 1675